Teclistamab With Talquetamab Shows a Manageable Safety Profile in RRMM
June 12th 2023Yael Cohen, MD, discusses the main safety findings from the phase 1/2 RedirecTT-1 trial, which is evaluating the combination of teclistamab-cqyv and talquetamab for the treatment of patients with relapsed/refractory multiple myeloma.
Watch